Prosecution Insights
Last updated: April 19, 2026
Application No. 18/255,943

NOVEL SCHIZOCHYTRIUM SP. STRAIN AND POLYUNSATURATED FATTY ACID PRODUCTION METHOD USING SAME

Final Rejection §DP
Filed
Jun 05, 2023
Examiner
CONSTANTINE, CHARLES Z
Art Unit
1657
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cj Cheiljedang Corporation
OA Round
2 (Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
3y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allow Rate
246 granted / 421 resolved
-1.6% vs TC avg
Strong +49% interview lift
Without
With
+49.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
20 currently pending
Career history
441
Total Applications
across all art units

Statute-Specific Performance

§101
5.3%
-34.7% vs TC avg
§103
31.2%
-8.8% vs TC avg
§102
20.1%
-19.9% vs TC avg
§112
27.7%
-12.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 421 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION The amendment received on 11/25/2025 is acknowledged. Claims 1, 7-9, and 14 have been amended. In light of applicant perfecting deposit of strain KCTC 14345BP, the rejection of claims 112(a) is withdrawn. In light of the amendment to the claims, the rejection of claims 1-14 under 35 U.S.C. 101 is withdrawn. The claims are now drawn to a mutated strain and product comprising the strain. Due to amendment to the claims, the double patenting rejection over 18708179 is withdrawn. No arguments regarding the remaining double patenting rejections have been presented and are thus maintained. Applicant’s arguments regarding the rejection of claims 7 and 8 under 35 U.S.C. 102/103 have been fully considered and are persuasive. The biomass claimed now comprises the claimed strain. While products of other strains may be similar, the current claims require the strain KCTC 14345BP. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 of copending Application No. 18023252 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because ’252 discloses compositions and biomass comprising cells of microalgae claims 1-14 which can be Schizochytrium (claim 7). The specification of ‘252 exemplifies the method using CD01-5004 (Accession No.: KCTC14345BP), and thus biomass made from this strain as well as cells of the strain fall within the scope of the claims of ‘252. This renders obvious the instant claim 1-8. Further claims 9-14 are claimed at such a high level that they encompass the process used to produce the product and thus these claims are rendered obvious by the claims of ‘252, as the steps required to produce the products and method of ‘252 result in the practicing of the instant claims, including the production of a bio-oil as these components will be present in the biomass produced that is collected. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 1-14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-2, 4-17 of copending Application No. 18023256 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because ‘256 claims a method of preparing a microalgae biomass and the biomass prepared (Claim 1-2, 4-17) and teaches that the microalgae that is prepared may be Schizochytrium (Claim 7). ‘256 exemplifies the method in the specification using CD01-5004 (Accession No.: KCTC14345BP, Example 2), and thus this strain falls within the scope of the claims. The steps of preparing the biomass will result in the biomass having bio-oil fatty acid being recovered as the biomass is recovered. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 1-14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of copending Application No. 18833735 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because ‘735 claims a method of preparing a microalgae biomass and the biomass produced from strain D01-5004 (Accession No.: KCTC14345BP, and the biomass prepared (Claim 1-19). The steps of preparing the biomass will result in the biomass having bio-oil fatty acid that is recovered as the biomass is recovered as well as cell lysis occurs in the growth and preparation of the biomass. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion No claim is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARLES Z CONSTANTINE whose telephone number is (571)270-5533. The examiner can normally be reached Mon-Fri 9-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Louise Humphrey can be reached at 571-272-5543. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARLES Z CONSTANTINE/Examiner, Art Unit 1657 /LOUISE W HUMPHREY/Supervisory Patent Examiner, Art Unit 1657
Read full office action

Prosecution Timeline

Jun 05, 2023
Application Filed
Aug 08, 2025
Non-Final Rejection — §DP
Nov 25, 2025
Response Filed
Jan 09, 2026
Final Rejection — §DP
Mar 24, 2026
Interview Requested
Apr 10, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12492418
METHOD FOR PREPARING THEAFLAVIN WITH IMMOBILIZED SUBSTRATE
2y 5m to grant Granted Dec 09, 2025
Patent 12473582
METHOD AND AGENTS FOR DETECTING LUCIFERASE ACTIVITY
2y 5m to grant Granted Nov 18, 2025
Patent 12435348
MICROBIAL CELLS FOR SPERMIDINE PRODUCTION
2y 5m to grant Granted Oct 07, 2025
Patent 12421481
PHOTON-INDUCED ACCELERATED ENZYMES AND BIOACTIVE COMPOUNDS ACCUMULATION IN BARLEY DURING MALTING
2y 5m to grant Granted Sep 23, 2025
Patent 12415871
METHOD OF PRODUCING A PECTIC POLYSACCHARIDE ISOLATE ENRICHED IN RHAMNOGALACTURONAN-I
2y 5m to grant Granted Sep 16, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+49.3%)
3y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 421 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month